Hashimoto's thyroiditis (HT) and Graves' disease (GD) are autoimmune thyroid diseases (AITD) in which multiple genetic factors are suspected to play an important role. Until now, only a few minor risk factors for these diseases have been identified. Susceptibility seems to be stronger in women, pointing toward a possible role for genes related to sex steroid action or mechanisms related to genes on the X-chromosome.
matase genes when either the patients with GD only, those with HT only, or those with any AITD were considered as affected. Linkage to the estrogen receptor ␤ could not be totally ruled out, partly due to incomplete mapping information for the gene itself at this time. The X-chromosome data revealed consistently positive LOD scores (maximum of 1.88 for marker DXS8020 and GD patients) when either definition of affectedness was considered. Analysis of the family data using a multipoint analysis with eight closely linked markers generated LOD scores suggestive of linkage to GD in a chromosomal area (Xq21. ) extending for about 6 cM and encompassing four markers. The maximum LOD score (2.5) occurred at DXS8020.
In conclusion, we ruled out a major role for estrogen receptor ␣ and the aromatase genes in the genetic predisposition to AITD. Estrogen receptor ␤ remains a candidate locus. We found a locus on Xq21. linked to GD that may help to explain the female predisposition to GD. Confirmation of these data in HT may require study of an extended number of families because of possible heterogeneity. (J Clin Endocrinol Metab 83: 3290 -3295, 1998) H ASHIMOTO'S thyroiditis (HT) and Graves' disease (GD) constitute a spectrum of autoimmune thyroid diseases (AITDs). They share an autoimmune pathogenesis, with a cellular and a humoral response to the thyroid gland. As a consequence, dysfunction of the gland itself may develop, characterized by hyperfunction in the case of GD and hypofunction in the case of HT. Although many of the mechanisms leading to the functional manifestations of AITDs have been illuminated in the past decades (1), the ultimate cause of the AITDs remain elusive. One clue to the understanding of the cause(s) of these diseases has come from the recognition of an inherited predisposition to AITD. Evidence in favor of a genetic basis for the AITDs is abundant. Familial clustering was reported as early as 1941 (2), whereas an increased incidence of thyroid autoimmune phenomena in relatives of patients has been known for many years (3, 4) . Limited studies in identical and nonidentical twins, although scanty, show a higher concordance rate in identical than in nonidentical twins (5), a clear evidence for a genetic component. GD and HT may share part of the genetic background, as both diseases may occur in different individuals of the same family (6) . However, the identification of causative genes has proven difficult (7) due to fact that the inheritance of the AITDs appears to be complex, probably multigenic, and with incomplete penetrance, as well as influenced by environmental factors such as infection (8) . As a consequence only a few genes [such as human leukocyte antigen (HLA)] have been identified to date; most represent minor risk-increasing genes and not necessary genes (7) . A distinctive feature of the AITDs is their predominance in women (9) . Epidemiological studies have consistently shown that in the general population the female to male prevalence ratio ranges from 5:1 to 10:1, with a peak incidence in the 2 decades that precede menopause (10) . The explanation for this imbalance is unclear. Animal studies indicate opposite effects of estrogen (up-regulating) and testosterone (downregulating) on the immune system, when given in supraphysiological amounts. (11, 12) . Altered tissue levels of estrogen, not detectable in the bloodstream, could cause increased estrogen influence on the immune system. Similarly, estrogen receptor abnormalities resulting in an altered sensitivity to normal levels of the hormone could be involved. An alternative explanation for gender-related differences in the risk for AITD could reside in genes on the sex chromosomes. Although an involvement of the Y-chromosome is virtually ruled out by the rarity of male to male transmission, modifications of X-chromosome genes in the setting of a complex inheritance pattern could explain the increased female risk for AITD. In keeping with this hypothesis, patients with Turner's syndrome show an increased prevalence of AITDs and thyroid autoimmune phenomena, such as positive antithyroid peroxidase and antithyroglobulin antibody tests (13) (14) (15) . The fact that similar findings are not observed in Klinefelter's syndrome patients (16) , who have two or more X-chromosomes but also a Y-chromosome, could be explained by a protective role exerted by Y-chromosome factors in both normal and Klinefelter's males.
The purpose of the present work was to determine genetic factors that may influence the gender-related imbalance in the prevalence of the AITDs. As a tool, we chose the method of linkage analysis in a large set of multiplex AITD families. We first analyzed the estrogen receptor ␣ and ␤ genes and the aromatase gene using microsatellite markers linked to these genes. Aromatase is a tissue enzyme that mediates the peripheral conversion of testosterone to estrogen and is an important determinant of estrogen levels at target organs. Estrogen receptor ␣ and ␤ [the latter recently described and partially mapped in humans (17, 18) ] are the mediators of estrogen actions at the nuclear level and represent additional candidates. We performed a two-point linkage analysis of the entire X-chromosome, using 20 microsatellite markers. We also used multipoint linkage analysis with a subset of these markers, selected because they gave positive logarithm of odds (LOD) scores in the 2-point analyses. Our results excluded linkage to the estrogen receptor ␣ and aromatase genes, whereas a role for the estrogen receptor ␤ gene could not be ruled out at this time. More interestingly, we found a locus on Xq21.33-22 that gave a LOD score of about 2.5, suggestive of linkage in a multipoint analysis in families with GD but not in those with HT. Xq21.33-22 contains the gene for X-linked agammaglobulinemia but is also predicted by partial physical mapping to contain many additional unidentified genes.
Subjects and Methods Patients
A total of 45 autoimmune thyroid disease multiplex families were analyzed. Forty-three families were of Caucasian descent, collected in New York, Italy, Britain, and Israel; 2 families were of Caribbean origin. Ten families had at least 2 members with GD, and 20 families had at least 2 members with HT. The remaining 16 families had at least 2 affected members, 1 of which had HT and the other had GD (mixed families). Fifty-five patients had GD, whereas 72 patients had HT. The female to male ratio was 4.4 among GD patients and 10.1 among HT patients. Also included were 178 unaffected family members. The diagnosis of GD was determined on the basis of documented clinical and laboratory evidence of present or past hyperthyroidism and the presence of at least 1 of the following: diffuse goiter, positive TSH receptor antibody tests, or presence of exophthalmos. The diagnosis of HT was based on evidence of thyroid hormone-replaced primary hypothyroidism with any of the following findings: diffuse, firm goiter or positive antithyroid peroxidase or antithyroglobulin tests. Blood samples were collected from all available affected and nonaffected members of each family after informed consent was obtained.
Microsatellite markers
Candidate genes. The estrogen receptor ␣ microsatellite marker (ER-1/ ER-2, GDB 196364, on chromosome 6q25.1) with a polymorphic informative content (PIC) of 0.913 and the aromatase marker (CYP19, GDB 156107), on chromosome 15q21 (PIC ϭ 0.913) were employed. At the present time, fine mapping and linkage data are not available for estrogen receptor ␤. However, the gene has been mapped to chromosome 14q22-24 by fluorescent in situ hybridization analysis (18) . We therefore analyzed two microsatellite markers, D14S63 (GDB 187894; PIC ϭ 0.785) and D14S258 (GDB 199369; PIC ϭ 0.800), at opposite ends of this region and 14 cM apart.
Chromosome X microsatellite markers. We employed a panel of 20 microsatellite markers, spanning the entire chromosome. Fifteen markers were part of a screening panel (Applied Biosystems, Foster City, CA), with intervals of about 10 cM. Five additional markers (see Fig. 1 ) were selected for their high PIC and their location from available on-line databases to explore in detail Xq21.33-22.
Allele determinations and typing. Whole blood was collected in ethylenediamine tetraacetate. Total genomic DNA was extracted using a commercial method (Puregene, Gentra Systems, Minneapolis, MN). PCR reactions were conducted using fluorescently labeled primers following the procedure of Weber and as previously described (19, 20) . Briefly, each PCR reaction was performed in 10 L of a mixture containing 50 ng total DNA, 0.12 U Taq polymerase (Perkin-Elmer, Foster City, CA), 5 pg fluorescently labeled primers, deoxyribose dinucleotide triphosphate, and 1.5 mmol MgCl 2 buffer. Fluorescently labeled PCR products were denatured and separated on an ABI-310 (Perkin-Elmer) automated sequencer. Allele typing was performed using Genotyper software (Perkin-Elmer) in a semiautomated fashion.
Statistical analyses
Two-point linkage analyses. Family data were analyzed using LIPED (21) . The hypothesis of positive linkage to candidate genes was tested assuming different models, either a dominant or a recessive mode of inheritance. For each mode of inheritance different levels of penetrance (20%, 40%, 50%, 60%, and 80%) were tested. These penetrances were used in the analyses of both the autosomal and X-chromosome markers. As both estrogen receptor ␣ and the aromatase markers were close to or within the respective candidate genes, a low (0.01) recombination fraction () was assumed in the model. For the two chromosome-14 markers and all X-chromosome markers, a range of values, from 0.01-0.5, was used to maximize the LOD score. The hypothesis of linkage was rejected when LOD scores were Ϫ2.0 or less. LOD scores were first obtained considering all affected subjects, i.e. with either GD or HT (AITD affectedness). Subsequently, to verify whether the studied genes could have a role in determining the type of AITD, analyses were run with the same parameters as above, but classifying only subjects with GD as affected or only subjects with HT disease as affected. In each of these analyses, mixed families were included and when the GD affectedness was examined; HT patients were considered as nonaffected and vice versa.
Multipoint linkage analysis. Genotype data for the area of interest of chromosome Xq21.33-22 (see Fig. 1 ) were analyzed in a multipoint analysis in an attempt to maximize the polymorphic information of each individual from the eight markers depicted in Fig. 1 . Using GeneHunter (22), we set inheritance parameters identical to those that gave the maximum LOD scores in the two-point analysis. Mapping information from the Genethon 1996 X-chromosome map was used (23) . All linkage analyses were run assuming a fixed general prevalence of 1% for both diseases. This is in reasonable accordance with epidemiological data from the literature (9), although prevalence data obtained using our strict diagnostic criteria are not available. Susceptibility allele frequencies for the different inheritance models were then derived according to the Hardy-Weinberg formula for the recessive and dominant models.
Results

Candidate genes
Negative LOD scores (Ϫ3) were obtained for the aromatase and the estrogen receptor ␣ genes, at a of 0.01 and assuming different models, when all patients with AITD were considered affected. These results ruled out linkage of these two genes to AITD as a whole. Similar results were observed when either the affectedness of GD or HT was considered. In this analysis, LOD scores less than Ϫ2 were not obtained in all models because of decreased sample size. Therefore, we were not able to formally reject linkage of either GD or HT for these candidate genes at penetrances less than 40%. However, LOD scores remained negative, (see Fig.   2 for the example of GD) in all models, arguing against linkage of either HT or GD to these two genes), As the exact position of the estrogen receptor ␤ gene with respect to the two markers on chromosome 14 was not known, a wide range of values was examined. Overall, negative LOD scores were observed in all affectednesses, but some small positive results were observed for D14S258, with a maximum LOD score of 0.87 when GD patients only were considered affected, at a of 0.1 and penetrance of 40%, assuming a dominant mode of inheritance. Therefore, linkage of AITD to the genes in this area (including estrogen receptor ␤) could not be conclusively ruled out, but there was little evidence in favor of linkage.
X-Chromosome markers
Two-point analysis. Most of the 20 markers gave negative or low positive LOD scores, not allowing formal rejection of linkage for all markers. However, marker DXS8020, on Xq21.33-22, gave a maximum LOD score of 1.8 in GD in the recessive mode of inheritance, with a penetrance of 40%. The same marker gave positive LOD scores, although at a lower level in both the AITD (1.33) and HT (1.55) categories. However, the latter maximum LOD scores were obtained under a different model (20% penetrance, dominant for both HT and AITD).
Multipoint analysis.
Genotype data from the eight markers depicted in the detail box of Fig. 1 , spanning a chromosomal region of about 41 cM were employed in the multipoint analysis. For each of the affectedness categories, the analysis was run under the model that gave the maximum LOD score for DXS8020 in the single point analysis.
When this approach was applied to all AITD and HT families, we were not able to confirm the results obtained in the single point analysis. HT gave a maximum LOD score of 0.56 in this analysis, close to DXS8063, whereas AITD gave a maximum LOD score of 0.26 at the same location. We investigated the reason for this discrepancy by looking at single pedigrees. Two large mixed families were relatively uninformative for DXS8020, contributing almost zero to the two-point analysis for this marker. However, these two families were very negative for nearby markers (such as DXS8063). In this situation the multipoint analysis drew most of the information from the latter marker(s), markedly reducing the total LOD score. Therefore, it was possible that significant heterogeneity existed in our dataset of HT families, affecting the results of linkage analyses for both HT and AITD. A heterogeneity LOD score of 1.5 was observed in this area, with ␣ ϭ 0.68, indicating possible heterogeneity.
In contrast, when the GD dataset was analyzed in the multipoint analysis, a maximum LOD score of 2.5 was obtained, coincident with DXS8020 (Fig. 3) . LOD scores above 2.3, which are suggestive of linkage (24), were observed across a segment of about 5 cM, encompassing DXS8020. The amount of polymorphic and linkage information contained in our dataset, as calculated by GeneHunter, was elevated across the whole area, reaching a maximum of 0.89 at DXS8020. For this reason additional positional information could only be obtained by adding more families to the dataset. When we allowed for heterogeneity, the LOD score was 2.5 and ␣ ϭ 0.99, which excluded the presence of significant heterogeneity.
Discussion
The precise basis for the genetic predisposition to AITD is unknown. Although an hereditary component in the pathogenesis of these diseases has long been recognized, the inheritance appears to be complex, probably involving multiple genes with variable penetrances. The problem up until now has been addressed mainly by association studies with a number of candidates (HLA and non-HLA) that contribute to the total risk for the diseases (7). None of these genes, however, has emerged as a necessary gene, thus failing to explain the familial clustering of the disease. In the past few years, human genome mapping efforts have provided investigators with detailed linkage maps, enabling the screening of the whole genome using linkage analysis. We have recently initiated the identification of susceptibility genes to AITD using linkage analysis and following two parallel investigative approaches: 1) analysis of candidate genes with known function, and 2) whole genome screening. With the second approach we have recently identified the first putative locus for GD on chromosome 14q31, GD-1 (20) . We also have excluded a major role for some immunoregulatory genes, such as the T cell receptors, the immunoglobulin heavy chain CTLA-4 (25) , and the HLA complex (26) . In the present work we have further investigated the genetic basis of AITD, attempting to address the reasons for the high prevalence of the diseases in women. We first analyzed candidate genes involved in estrogen action at the tissue level. For two of them, the estrogen receptor ␣ and aromatase genes, precise mapping data are available in the literature. We could, therefore, use microsatellite markers tightly linked to the genes themselves. This strongly enhanced the power to detect linkage by reducing the chances of recombinations between the marker and the candidate gene. Our data rule out the estrogen receptor ␣ and aromatase genes as necessary genes for AITD. We also did not find any evidence of linkage to the chromosomal region containing the estrogen receptor ␤ gene. Detailed mapping information for this gene was lacking, and therefore, our analysis obtained with two markers in the area of the receptor gene itself, but not tightly linked to it, may not be powerful enough to detect linkage.
The analysis of a panel of X-chromosome markers yielded interesting positive LOD scores for all three affectedness statuses for marker DXS8020, located on Xq21.33-22. Subsequent multipoint analysis with dense markers in this area provided a maximum multipoint LOD score of 2.5 on marker DXS8020 for GD patients. There may be more than one reason why data from the single point analyses were not confirmed for HT and AITD subsets of patients. It seems possible that the genetic predisposition to HT may be heterogeneous, i.e. determined by different genes in different families. It should also be remembered that HT has a later onset and that the spectrum of its clinical manifestations, ranging from microscopic thyroid lymphocytic infiltration with serum autoantibodies to the full-blown picture of goiter and hypothyroidism, is highly variable, making diagnostic criteria somewhat less reliable. In contrast, the diagnosis of GD is readily made based on the clinical picture and the high specificity of TSH receptor antibody as diagnostic markers (27) . It is noteworthy that, in fact, the results of the multipoint analysis did not rule out linkage of HT to markers on Xq21.33-22, but only failed to confirm the single point anal-
ysis, leaving open the possibility that adding more families or using more restrictive criteria for classifying subtypes of HT may in the future show significant linkage for this disease also. Alternatively, it is possible that the type of autoimmune thyroid response is finally determined by other genes, specific for the single AITD type.
A LOD score of 2.5, as we found in our GD families, has been considered suggestive of linkage (24) . When many different models are explored, correction for multiple testing has been suggested, by subtracting 0.3-0.6 from the resulting LOD score (28) . Even with this very conservative correction, our data remain suggestive of linkage (24) . The X-chromosome was chosen because of the disproportionately high prevalence of AITD in women. The well established increase in the incidence of thyroid autoimmunity in patients with Turner's syndrome is another indication of a possible involvement of the X-chromosome (15) . By large, most X-linked monogenic inherited traits are fully recessive and, therefore, clinically evident in men alone. However, AITD inheritance is complex and does not follow a readily identifiable (Mendelian) pattern. For example, genes on the X-chromosome with a dose-dependent effect and interacting with other genes could explain the female predisposition to AITD. It should be noted that although for mathematical reasons it was necessary to set linkage analyses under certain simple models, these also may not accurately describe the real situation, and that when studying multigenic diseases, the concepts of recessive vs. dominant and of penetrance represent approximations. In principle, when the inheritance model of disease is not known, a nonparametric method is preferable, because it prevents the need for multiple testing, therefore reducing the risks of false positives. However, in classical linkage analysis with complex families, this approach is also less sensitive because it discards the amount of information provided by nonaffected members (29) . For this reason we used only parametric data.
Xq21.33-22 has now been physically mapped (30) . Genes for several X-linked diseases map to this region, such as Alport's syndrome, diffuse leiomyomatosis, Fabry's disease, and the gene for X-linked agammaglobulinemia, or Bruton tyrosine kinase (BTK). BTK encodes for a tyrosine kinase protein of the src protooncogene family (31), expressed in B lymphocytes and important in the development of B lymphocytes. Several mutations have been reported in patients with X-linked agammaglobulinemia, resulting in a nonfunctional protein (31) . The mouse homologous to BTK (xid) has been shown to modulate the expression of collagen autoimmunity in a susceptible strain (32) by exerting a permissive effect on the autoimmune genetic background. Physical mapping has shown BTK to map between DXS990 and DXS1106 (30) , to a region containing the maximum LOD score obtained in our analysis. BTK, therefore, represents a possible candidate as a susceptibility gene for GD. The region also contains a high number of CpG islands (33), a feature that predicts the presence of many additional genes (34) .
In summary, we have shown that the estrogen receptor ␣ and aromatase genes are not susceptibility genes for AITD, whereas the estrogen receptor ␤ gene is a possible candidate that deserves further study. We found suggestive linkage of GD to a locus on chromosome Xq21.33-22 that contains a susceptibility gene for the disease. Further study with independent datasets is warranted to obtain confirmation of our findings.
